The FDA's Pharmacy Compounding Advisory Committee voted 8-6 (one abstention) on July 23, 2026, to recommend adding BPC-157 to the Section 503A Bulks List for uses such as ulcerative colitis treatment, marking a key step after its earlier removal from Category 2 in April 2026
The immune system gets activated and starts treating healthy cells as bacteria or viruses, trying to fight them off and kill them
Peak fractions were concentrated to ~7 mg/ml for cryo-EM data collection
However: It can cause water retention, increased appetite, and insulin sensitivity changes in some users
Mild side effects may occur some people feel tired, achy or notice redness at the needle site but these usually fade quickly
But certain medications (like antidepressants), supplements and substances can raise serotonin levels